Focused On-demand Library for Pituitary-specific positive transcription factor 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P28069

UPID:

PIT1_HUMAN

Alternative names:

Growth hormone factor 1

Alternative UPACC:

P28069; O75757; Q15132; Q15133; Q9UD34; Q9UEL3

Background:

Pituitary-specific positive transcription factor 1, also known as Growth hormone factor 1, plays a pivotal role in the development of the anterior pituitary gland. It specifically binds to the consensus sequence 5'-TAAAT-3', activating growth hormone and prolactin genes. This transcription factor is crucial for the specification of lactotrope, somatotrope, and thyrotrope phenotypes, essential for normal pituitary function.

Therapeutic significance:

The protein is linked to Combined Pituitary Hormone Deficiency (CPHD1), characterized by growth hormone, prolactin, and thyroid-stimulating hormone deficiencies. Understanding the role of Pituitary-specific positive transcription factor 1 could open doors to potential therapeutic strategies for treating CPHD1, offering hope for patients suffering from severe growth deficiency and intellectual disability.